abaloparatide vs aflibercept
Side-by-side comparison of abaloparatide and aflibercept Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Tymlos
Eylea
Tymlos is a medicine to treat osteoporosis. It helps make your bones stronger and less likely to break.
AHZANTIVE is a medicine used to treat certain eye problems. It helps to stop blood vessels from growing and leaking in the eye.
Tymlos treats osteoporosis in women after menopause and in men. It is for people who have a high chance of breaking a bone. This includes those who have already had a bone break due to osteoporosis or have other risk factors. It can also be used if other osteoporosis treatments did not work or could not be tolerated.
AHZANTIVE treats wet age-related macular degeneration (AMD). It also treats swelling in the macula (the central part of the retina) caused by retinal vein occlusion (RVO) or diabetic macular edema (DME). Additionally, it can treat diabetic retinopathy (DR), an eye disease caused by diabetes.
Tymlos is similar to a natural hormone in your body. It helps your body build new bone. This makes your bones stronger and less likely to break.
AHZANTIVE is a VEGF inhibitor. VEGF is a protein that promotes the growth of new blood vessels. By blocking VEGF, AHZANTIVE helps to reduce the growth of abnormal blood vessels in the eye and decrease leakage.
- • High calcium in your urine
- • Feeling dizzy
- • Feeling sick to your stomach
- • Headache
- • Feeling your heart beat fast or irregularly
- • Bleeding in the eye
- • Eye pain
- • Clouding of the lens of the eye (cataract)
- • Separation of the vitreous gel from the retina
- • Spots in your vision
- Headache 4,180
- Feeling sick to your stomach 3,222
- Feeling dizzy 3,122
- Feeling tired 2,742
- Increased heart rate 2,139
- Death 7,853
- Trouble seeing 2,013
- Using the medicine for something it's not approved for 1,509
- Loss of sight 1,459
- Eye infection 1,372
Tymlos may increase the risk of bone cancer (osteosarcoma). You should not take this medicine if you have certain conditions that increase this risk. These include Paget's disease, bone cancer, radiation treatment to your bones, or certain hereditary disorders. If you have symptoms of feeling dizzy, palpitations, tachycardia, or nausea, you should sit or lie down.
Injections with AHZANTIVE may cause serious eye infections (endophthalmitis), separation of the retina (retinal detachment), and inflammation of blood vessels in the retina. Tell your doctor right away if you have any signs of these problems. AHZANTIVE may also increase the risk of blood clots that can cause stroke or heart attack.
Tymlos is not for women who could get pregnant. It is not known if Tymlos can harm an unborn baby or pass into breast milk.
It is not known if AHZANTIVE can harm an unborn baby. AHZANTIVE should be used during pregnancy only if the benefit justifies the risk. It is also not known if AHZANTIVE passes into breast milk.
Also Compare — Nearby Drugs
Compare aflibercept with
How to Read This abaloparatide vs aflibercept Comparison
abaloparatide is classified in the PTHrP Analog drug class, while aflibercept sits within the Anti-VEGF (Ophthalmic Injection) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, abaloparatide has 15,405 submissions while aflibercept has 14,206. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between abaloparatide and aflibercept — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.